Elan Corp.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: JP3167680002
JPY
705.00
-10 (-1.4%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Towa Pharmaceutical Co., Ltd.
Mochida Pharmaceutical Co., Ltd.
Elan Corp.
Earth Corp.
ASKA Pharmaceutical Holdings Co., Ltd.
Zeria Pharmaceutical Co., Ltd.
Katakura Industries Co., Ltd.
KYORIN Pharmaceutical Co., Ltd.
Torii Pharmaceutical Co., Ltd.
Kaken Pharmaceutical Co., Ltd.
Nxera Pharma Co., Ltd.
Why is Elan Corp. ?
1
Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 24.54%
  • Healthy long term growth as Net Sales has grown by an annual rate of 17.15% and Operating profit at 18.95%
  • Company has very low debt and has enough cash to service the debt requirements
2
Negative results in Jun 25
  • ROCE(HY) Lowest at 19.75%
  • INTEREST COVERAGE RATIO(Q) Lowest at 11,999.38
  • RAW MATERIAL COST(Y) Grown by 8.34% (YoY)
3
With ROE of 19.68%, it has a expensive valuation with a 4.05 Price to Book Value
  • The stock is trading at a premium compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of -5.62%, its profits have fallen by -4.8%
4
Consistent Underperformance against the benchmark over the last 3 years
  • Along with generating -5.62% returns in the last 1 year, the stock has also underperformed Japan Nikkei 225 in each of the last 3 annual periods
stock-recommendationReal-Time Research Report
Verdict Report
How much should you hold?
  1. Overall Portfolio exposure to Elan Corp. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Elan Corp. for you?

Low Risk, Low Return

Absolute
Risk Adjusted
Volatility
Elan Corp.
-5.62%
-0.62
30.67%
Japan Nikkei 225
28.54%
1.11
25.75%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
17.15%
EBIT Growth (5y)
18.95%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.37
Sales to Capital Employed (avg)
3.89
Tax Ratio
33.49%
Dividend Payout Ratio
33.38%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
83.83%
ROE (avg)
24.54%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
21
Industry P/E
Price to Book Value
4.05
EV to EBIT
12.26
EV to EBITDA
9.35
EV to Capital Employed
5.83
EV to Sales
0.92
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
47.58%
ROE (Latest)
19.68%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

4What is working for the Company
DEBTORS TURNOVER RATIO(HY)

Highest at 6.26%

NET SALES(Q)

At JPY 13,406.87 MM has Grown at 18.04%

-13What is not working for the Company
ROCE(HY)

Lowest at 19.75%

INTEREST COVERAGE RATIO(Q)

Lowest at 11,999.38

RAW MATERIAL COST(Y)

Grown by 8.34% (YoY

DEBT-EQUITY RATIO (HY)

Highest at -37.53 %

INTEREST(Q)

Highest at JPY 10.47 MM

Here's what is working for Elan Corp.
Net Sales
At JPY 13,406.87 MM has Grown at 18.04%
Year on Year (YoY)
MOJO Watch
Near term sales trend is positive

Net Sales (JPY MM)

Debtors Turnover Ratio
Highest at 6.26%
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Here's what is not working for Elan Corp.
Interest
At JPY 10.47 MM has Grown at 30.98%
period on period (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Interest Coverage Ratio
Lowest at 11,999.38
in the last five periods
MOJO Watch
The company's ability to manage interest payments is deteriorating

Operating Profit to Interest

Interest
Highest at JPY 10.47 MM
in the last five periods and Increased by 30.98% (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Debt-Equity Ratio
Highest at -37.53 %
in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Raw Material Cost
Grown by 8.34% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales